Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
| ▸ | HEXA | P06865 | 1/20 | 0.38 |
| ▸ | HEXB | P07686 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489493 | 0.85 | HDAC4 (0.50) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL28792762 | 0.84 | ABL1 (0.55) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL9959026 | 0.83 | ABL1 (0.46) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL7024625 | 0.83 | ABL1 (0.46) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL430965 | 0.83 | ABL1 (0.46) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL10319286 | 0.83 | CLK4 (0.41) | ABL1ABCB1BCRAPPRAB9A | |
| SCHEMBL1679543 | 0.81 | ABL1 (0.44) | ABL1ABCB1BCRHDAC4HDAC2 | |
| SCHEMBL27522250 | 0.78 | DPP4 (0.47) | HDAC4HDAC2HDAC8ENPP1HTR7 | |
| SCHEMBL1443909 | 0.77 | ENPP1 (0.39) | ABL1ENPP1FFAR1FFAR4HTR7 | |
| SCHEMBL1679371 | 0.77 | ABL1 (0.50) | ABL1ABCB1BCRHDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447478-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11034687-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200308166-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3271355-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-10723729-B2 | BACE1 inhibitors | Hoffmann-Le Roche Inc. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10604544-B2 | Methods for preparation of bile acids and derivatives thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190337936-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-11-07 | — | — | US | disclosed |
| US-10399969-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| US-20180319787-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2012139993-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-18 | — | — | WO | disclosed |
| EP-2509965-A1 | 2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2012119883-A1 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225858-A1 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-06 | — | — | US | disclosed |
| WO-2011069934-A1 | 2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144097-A1 | 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| US-6465650-B1 | INTERMEDIATE STEPS IN PREPARING PEPTIDE NUCLEIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-15 | — | — | US | disclosed |
| US-6075143-A | USEFUL FOR FORMING PEPTIDE NUCLEIC ACIDS OR HYBRID OF PEPTIDE NUCLEIC ACIDS AND DEOXYNUCLEIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337936-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | ABL1 4597/4885ABCB1 196/4885BCR 3930/4885 |
| US-11447478-B2 | BACE1 inhibitors | BACE1, BACE2, APP | ABL1 4646/4885ABCB1 189/4885BCR 3985/4885 |
| US-10399969-B2 | BACE1 inhibitors | BACE1, BACE2, APP | ABL1 4597/4885ABCB1 196/4885BCR 3930/4885 |
| US-20180319787-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | ABL1 4597/4885ABCB1 196/4885BCR 3930/4885 |
| US-20200308166-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | ABL1 4597/4885ABCB1 196/4885BCR 3930/4885 |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | ABL1 4479/4885ABCB1 168/4885BCR 4097/4885 |
| US-10723729-B2 | BACE1 inhibitors | BACE1, BACE2, APP | ABL1 4597/4885ABCB1 196/4885BCR 3930/4885 |
| US-10604544-B2 | Methods for preparation of bile acids and derivatives thereof | SLC10A2, SLC10A1, NR1H4 | ABL1 1028/4885ABCB1 151/4885BCR 2468/4885 |
| US-20120225858-A1 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | ABL1 3898/4885ABCB1 71/4885BCR 2089/4885 |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | NEU4, NEU2, NEU1 | ABL1 68/4885ABCB1 2971/4885BCR 573/4885 |
| US-11034687-B2 | BACE1 inhibitors | BACE1, BACE2, APP | ABL1 4597/4885ABCB1 196/4885BCR 3930/4885 |
| US-20110144097-A1 | 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES | BACE2, BACE1, APP | ABL1 3639/4885ABCB1 369/4885BCR 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.